{
  "nctId": "NCT02922478",
  "briefTitle": "Role of Comorbidities in Chronic Heart Failure Study",
  "officialTitle": "Role of Comorbidities in Chronic Heart Failure (RoC-HF) Study",
  "protocolDocument": {
    "nctId": "NCT02922478",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2018-08-07",
    "uploadDate": "2018-11-29T02:46",
    "size": 573188,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT02922478/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [],
  "studyType": "OBSERVATIONAL",
  "enrollmentInfo": {
    "enrollmentCount": 205,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2016-09",
    "completionDate": "2018-12-20",
    "primaryCompletionDate": "2018-12-20",
    "firstSubmitDate": "2016-09-28",
    "firstPostDate": "2016-10-04"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n1. Age \\>= 18\n2. NYHA (New York Heart Association) class II-IV symptoms\n3. Left ventricular ejection fraction \\< 50% at Visit 1.\n4. Treatment according to current Heart Failure Guidelines of the European Society of Cardiology\n5. Willingness and ability to provide signed informed consent form (ICF) prior to participation in any study-related procedures\n6. Previous diagnosis of heart failure with reduced ejection fraction defined as symptomatic left ventricular ejection \\< 40% requiring optimization of heart failure therapy\n\nExclusion Criteria:\n\n1. Unplanned hospitalization within 1 month prior to the Baseline Visit.\n2. Discontinuation or initiation of a pharmacologic or device treatment for HFrEF within 1 month prior to the baseline visit.\n3. Coronary or peripheral revascularization procedures, valvular procedures, OR any major surgical procedure within 3 months prior to the Screening Visit.\n4. Acute coronary syndrome (ACS), stroke or transient ischemic attack (TIA) within 3 months prior to the Screening Visit.\n5. Any acute illness\n6. Disease reducing life expectancy to \\< 1 year, except HFrEF\n7. Recipient of any organ transplant\n8. Primary significant valve disease (at least moderate to severe valve disease)",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Prevalence of osteoporosis in chronic heart failure",
        "timeFrame": "1 day"
      },
      {
        "measure": "Prevalence of vertebral fractures in chronic heart failure",
        "timeFrame": "1 day"
      }
    ],
    "secondary": [
      {
        "measure": "Peripheral and central pulse wave velocity",
        "timeFrame": "24 hours"
      },
      {
        "measure": "24-hours systolic and diastolic blood pressure",
        "timeFrame": "24 hours"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 2,
      "secondaryCount": 2,
      "otherCount": 0,
      "totalCount": 4
    },
    "studyDesign": {
      "phases": [],
      "isRandomized": false,
      "isMasked": true
    },
    "overallComplexityScore": 49,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-21T22:34:12.947Z",
  "dataSource": "ClinicalTrials.gov API v2 - Mass Collection"
}